Signal Characterization of Insulin Glargine Product Groups in the United States Food and Drug Administration Adverse Event Reporting System
Pharmacoepidemiology · 30.06.2026 · 5 (3) · 21
DOI: 10.3390/pharma5030021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology, online erschienen am 30.06.2026. Verfasst von Elaf M. Basheer und 1 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: We described adverse event reporting patterns for insulin glargine marketed as 100 units/mL (Lantus), 300 units/mL (Toujeo), and 100 units/mL biosimilars (Basaglar/Semglee).
Methods
We analyzed Food and Drug Administration Adverse Event Reporting System (FAERS) reports received from 2015 through 2025 that listed insulin glargine as a primary or secondary suspect. Reports were grouped by trade name into standard-strength originator (Lantus), high-strength (Toujeo), and biosimilar products. We defined a composite serious outcome (death, life-threatening event, hospitalization, or disability). Logistic regression adjusted for age, sex, reporter type, and year received; Firth’s penalized regression was used for sparse death and hospitalization outcomes. Sensitivity analyses restricted to reports without concomitant suspect products, overlapping calendar windows, and healthcare professional reports. Geographic reporting patterns were analyzed by country.
Results
We included 43,905 eligible reports (Lantus: 35,927; Toujeo: 3699; biosimilars: 4279). Unadjusted death was highest for Lantus (8.2%) followed by biosimilars (6.0%) and Toujeo (3.2%). In the primary adjusted model (n = 28,519), reports listing Toujeo had lower adjusted reporting odds of the composite serious outcome compared with Lantus (aOR 0.88, 95% CI 0.81–0.96), while biosimilars showed higher odds (aOR 1.24, 95% CI 1.11–1.38). The biosimilar association was not robust: it attenuated without concomitant drugs (aOR 1.07, 95% CI 0.92–1.23) and reversed in healthcare professional reports (aOR 0.65, 95% CI 0.49–0.87). Device-related events were lower for biosimilars (aOR 0.58) and Toujeo (aOR 0.85). Geographic heterogeneity was extreme (Egypt 76.9% death vs. Italy 0.8%), and the US protective association reversed in recent years.
Conclusions
After adjustment for report-level characteristics, Toujeo was associated with lower reporting odds of serious outcomes, while biosimilar findings were inconsistent across sensitivity analyses and driven by consumer reporting. Geographic heterogeneity and the Egypt outlier underscore the fragility of cross-country comparisons in spontaneous reporting data. These findings reflect reporting-behavior heterogeneity rather than differential product safety.
Zitieren
APA
Basheer, E. M., & Aladul, M. I. (2026). Signal Characterization of Insulin Glargine Product Groups in the United States Food and Drug Administration Adverse Event Reporting System. Pharmacoepidemiology, 5(3), 21. https://doi.org/10.3390/pharma5030021
Vancouver
Basheer EM, Aladul MI. Signal Characterization of Insulin Glargine Product Groups in the United States Food and Drug Administration Adverse Event Reporting System. Pharmacoepidemiology. 2026;5(3):21. doi:10.3390/pharma5030021
BibTeX
@article{Basheer2026,
author = {Basheer, Elaf M. and Aladul, Mohammed Ibrahim},
title = {Signal Characterization of Insulin Glargine Product Groups in the United States Food and Drug Administration Adverse Event Reporting System},
journal = {Pharmacoepidemiology},
year = {2026},
volume = {5},
number = {3},
pages = {21},
doi = {10.3390/pharma5030021}
}
EUVIMED